Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease
Alimentary Pharmacology and Therapeutics Feb 01, 2018
Christensen B, et al. - This study was performed to describe the effect of the α4β7 integrin antibody, vedolizumab, on liver biochemistry and disease activity in patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). Liver biochemistry did not improve with vedolizumab treatment in patients with PSC and IBD. However, this treatment was correlated with improvement in bowel disease and a favourable safety profile.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
